BridgeBio Pharma's compensation committee has approved equity grants totaling 76,701 restricted stock units for 34 newly hired employees, the company disclosed in a regulatory filing. The grants, approved on February 12, 2026, represent inducement awards made in connection with employment under Nasdaq Listing Rule 5635(c)(4), which permits companies to grant equity to new employees outside of shareholder-approved equity plans.
The restricted stock units will vest according to a standard four-year schedule, with 25 percent of each grant vesting after the first year of employment and the remaining 75 percent vesting in equal quarterly installments over the subsequent three years. All vesting is contingent upon the employees' continued employment with the company.
Inducement grants under Nasdaq rules allow companies to attract talent by offering equity compensation without obtaining shareholder approval, provided the grants are material inducements to employment and disclosed publicly. BridgeBio's grant program aligns with industry practice for recruiting new personnel to support ongoing business operations and research initiatives.